DexCom Sees Unusually Large Options Volume (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) was the target of some unusual options trading on Thursday. Stock traders acquired 10,495 call options on the stock. This is an increase of 87% compared to the average volume of 5,616 call options.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Raymond James boosted their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday. Canaccord Genuity Group boosted their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday. UBS Group boosted their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Citigroup boosted their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $141.67.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $124.34 on Friday. DexCom has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $49.24 billion, a price-to-earnings ratio of 94.92, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20. The business has a 50 day simple moving average of $131.13 and a 200-day simple moving average of $118.30.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. As a group, equities research analysts expect that DexCom will post 1.76 earnings per share for the current year.

Insider Activity

In other news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock valued at $25,530,859 in the last three months. Corporate insiders own 0.41% of the company’s stock.

Institutional Investors Weigh In On DexCom

Institutional investors have recently made changes to their positions in the company. DSM Capital Partners LLC bought a new stake in shares of DexCom in the 4th quarter valued at approximately $28,000. Riverview Trust Co acquired a new stake in DexCom in the first quarter worth $32,000. Valley National Advisers Inc. increased its position in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the period. MV Capital Management Inc. increased its position in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares during the period. Finally, Smithfield Trust Co increased its position in DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.